California Pacific Medical Center Research Institute Report issue

Foundation Phase 2 Phase 3

Organization Overview

First Clinical Trial
2016
NCT02913417
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

California Pacific Med Center Research Inst. | California Pacific Medical Center (CPM) Research Institute | David Minor, MD

Active Ingredients

Drugs in Phase 3 Trials (1)

bone marrow derived mesenchymal stem cells (1 trial)

Drugs in Phase 2 Trials (2)

ipilimumab (yervoy) (1 trial)

nivolumab (opdivo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 3)

Melanoma (Phase 2)

Motor Neuron Disease (Phase 3)

Neoplasm Metastasis (Phase 2)

Uveal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3